Autolus Therapeutics plc (NASDAQ:AUTL) Shares Sold by Alps Advisors Inc.

Alps Advisors Inc. cut its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTLGet Rating) by 42.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 53,931 shares of the company’s stock after selling 39,502 shares during the quarter. Alps Advisors Inc.’s holdings in Autolus Therapeutics were worth $153,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in AUTL. Frazier Life Sciences Management L.P. acquired a new position in shares of Autolus Therapeutics during the 1st quarter worth $15,624,000. Deep Track Capital LP acquired a new position in shares of Autolus Therapeutics during the 1st quarter worth $1,595,000. MAI Capital Management acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth $1,034,000. Nantahala Capital Management LLC grew its stake in shares of Autolus Therapeutics by 6.6% during the 1st quarter. Nantahala Capital Management LLC now owns 4,346,327 shares of the company’s stock worth $18,124,000 after purchasing an additional 268,818 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of Autolus Therapeutics by 144.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 375,514 shares of the company’s stock worth $1,566,000 after purchasing an additional 222,093 shares during the period. 55.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Needham & Company LLC lowered their price target on shares of Autolus Therapeutics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, August 5th.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL opened at $2.45 on Thursday. The stock has a market cap of $223.27 million, a price-to-earnings ratio of -1.32 and a beta of 1.54. Autolus Therapeutics plc has a 52 week low of $1.96 and a 52 week high of $6.94. The company’s 50-day moving average price is $2.60 and its 200 day moving average price is $2.79. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.07.

Autolus Therapeutics Company Profile

(Get Rating)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.

Featured Articles

Want to see what other hedge funds are holding AUTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Autolus Therapeutics plc (NASDAQ:AUTLGet Rating).

Institutional Ownership by Quarter for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.